apixaban - etoricoxib
apixaban - etoricoxib
Klass : C0
Visa all info
Skriv ut
Kontakta oss
ELIQUIS (apixaban), Bistol-Meyers Squibb/Pfizer EEIG. SPC. 2011.
, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877-85.
Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol. 2014.
Lee MT, Park KY, Kim MS, et al. Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding. Yonsei Med J. 2020 Sep;61(9):741-9.
Dalgaard F, Mulder H, Wojdyla DM, et al. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation. 2020 Jan 7;141(1):10-2.
Kent AP, Brueckmann M, Fraessdorf M, et al. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):255-67.
Kreutz R, Haas S, Holberg G, Lassen MR, Mantovani LG, Schmidt A et al. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. Br J Clin Pharmacol. 2016;81:724-34.
Olsen AS, McGettigan P, Gerds TA, et al. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):292-300.
- ELIQUIS (apixaban), Bistol-Meyers Squibb/Pfizer EEIG. SPC. 2011.
- , Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877-85.
- Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol. 2014.
- Lee MT, Park KY, Kim MS, et al. Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding. Yonsei Med J. 2020 Sep;61(9):741-9.
- Dalgaard F, Mulder H, Wojdyla DM, et al. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation. 2020 Jan 7;141(1):10-2.
- Kent AP, Brueckmann M, Fraessdorf M, et al. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):255-67.
- Kreutz R, Haas S, Holberg G, Lassen MR, Mantovani LG, Schmidt A et al. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. Br J Clin Pharmacol. 2016;81:724-34.
- Olsen AS, McGettigan P, Gerds TA, et al. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):292-300.